Standout Papers

Efficacy, Immunogenici... 2021 2026 2022 2024378
  1. Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons (2025)
    Edward E. Walsh, Daniel Eiras et al. Clinical Infectious Diseases
  2. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants (2021)
    Jianying Liu, Yang Liu et al. Nature
  3. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera (2021)
    Alexander Muik, Ann-Kathrin Wallisch et al. Science
  4. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera (2021)
    Xuping Xie, Yang Liu et al. Nature Medicine
  5. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022)
    Alexander Muik, Bonny Gaby Lui et al. Science

Immediate Impact

3 by Nobel laureates 34 from Science/Nature 66 standout
Sub-graph 1 of 17

Citing Papers

Spike deep mutational scanning helps predict success of SARS-CoV-2 clades
2024 StandoutNature
Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants
2024 Standout
8 intermediate papers

Works of Kena A. Swanson being referenced

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
2022
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
2022
and 4 more

Author Peers

Author Last Decade Papers Cites
Kena A. Swanson 1405 390 140 375 37 1.9k
Naoko Iwata‐Yoshikawa 1506 379 59 318 35 2.0k
David J. Gregory 1417 530 78 968 31 2.8k
Xinrong Tao 1289 236 126 391 57 1.9k
Chee Wah Tan 2441 314 60 560 59 3.0k
David R. Martinez 1005 331 84 274 60 1.7k
Rita E. Chen 2223 308 83 785 27 2.8k
Blake M. Hauser 2227 201 59 685 51 2.7k
Sam Afkhami 1037 241 144 347 33 1.7k
Neta S. Zuckerman 1191 170 79 380 71 1.9k
Xianwen Zhang 1814 212 112 651 46 2.5k

All Works

Loading papers...

Rankless by CCL
2026